Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression

BMC Psychiatry

Nikiforos V Angelopoulos²  Andreas A Rizoulis¹  Katerina A Rizouli³  Sokratis E Karaoulanis² 

[1] Department of Endocrinology, University Hospital of Larissa, University of Thessalia, Larissa, Greece;Department of Psychiatry, University Hospital of Larissa, University of Thessalia, Mezourlo, Larissa, P.O. Box 41110, Greece;Department of Immunology, University Hospital of Larissa, University of Thessalia, Larissa, Greece

关键词: Selective serotonin reuptake inhibitors;    Reproductive hormones;    Acute-phase response proteins;    Depression;    Perimenopause;   

Others  :  1123533
DOI  :  10.1186/1471-244X-14-164

 received in 2013-12-16, accepted in 2014-05-19,  发布年份 2014

【 摘 要 】

Background

Major depression is associated with higher plasma levels of positive acute-phase proteins, as well as with lower plasma levels of negative acute-phase proteins. The aim of this study is to examine the levels of acute-phase response proteins and whether these levels are influenced by reproductive hormones and antidepressant medication in the perimenopausal depression.

Methods

Sixty-five women (age range: 40–58 years old) participated in this study. All women were in the perimenopausal phase. The diagnosis of depression was made through a psychiatric interview and with the aid of Hamilton Depression Rating Scale 17 (HAM-D 17). The acute-phase response proteins, such as haptoglobin (HP), transferrine (TRf), α1-antitrypsin, complement protein 3 (C3), complement protein 4 (C4) and C-reactive protein (CRP) and the reproductive hormones, for example follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2), were analyzed using standard laboratory methods. Pearson’s correlations were applied to evaluate the relationship between acute-phase proteins and hormones.

Results

Perimenopausal women were divided into three groups. The first group consisted of normal controls, the second one involved depressed perimenopausal women, who were taking selective serotonin reuptake inhibitors (SSRIs), and the third one included depressed women that were not treated with SSRIs. Depressed women in perimenopause, when being compared to non-depressed women, did not differ as to serum levels of acute-phase proteins. There was a positive correlation between HP and E2 in depressed perimenopausal women, who were not taking SSRIs.

Conclusions

The lack of association between acute-phase proteins and depressive mood mentioned in this study does not support previous findings in patients with major depression. This negative finding in perimenopausal depression indicates either the absence or a more complex nature of the interactions between acute-phase proteins, low-grade inflammation and depression. The hormonal profile of women is a part of this complexity, because it seems that in perimenopause the hormonal changes are accompanied by changes of acute-phase response proteins. Particularly, in perimenopausal depression, there is an interaction between HP and E2. Therefore, it seems that perimenopause is a period of a woman’s life during which hormonal, immune and metabolic changes occur and interact with each other making women vulnerable to depression.

【 授权许可】

   
2014 Karaoulanis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
• [2]Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1 and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
• [3]Maes M: Evidence for an immune response in major depression: a review and major hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:11-38.
• [4]Wium-Andersen MK, Orsted DD, Nielsen SF, Nordestgaard BG: Elevated C-reactive protein levels, psychological distress and depression in 73.131 individuals. JAMA Psychiatry 2013, 70(2):176-184.
• [5]Ford DE, Erlinger TP: Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004, 164(9):1010-1014.
• [6]Danner M, Kasl SV, Abramson JL, Vaccarino V: Association between depression and elevated C-reactive protein. Psychosom Med 2003, 65(3):347-356.
• [7]Legros S, Mendlewicz , Wybran J: Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 1985, 235:9-11.
• [8]Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Cytokine production and serum proteins in depression. Scand J Immunol 1995, 41:534-538.
• [9]Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K: Indicators of immune activation in major depression. Psychiatry Res 1996, 64:161-167.
• [10]Sluzewska A, Rybakowski J, Sobieska M, Wiktorowicz K: Concentration and microheterogeneity glycophorms of a1-acid glycoprotein in major depressive disorder. J Affect Disord 1996, 39:149-155.
• [11]Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A: Acute phase proteins in major depression. J Psychosom Res 1997, 43:529-534.
• [12]Douglas KM, Taylor AJ, O’Malley PG: Relationship between depression and C- reactive protein in a screening population. Psychosom Med 2004, 66(5):679-683.
• [13]Joyce PRHCR, Mulder RT, Sellman JD, Willson DA, Boswell DR: Elevated levels of acute phase proteins in major depression. Biol Psychiatry 1992, 32:1035-1041.
• [14]Maes M, Scharpe S, Bosmans E, Vandewoude M, Suy E, Uyttenbroeck W, Cooreman W, Vandervorst C, Raus J: Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 1992, 16:501-515.
• [15]Zorilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorcle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001, 15:199-226.
• [16]Maes M, Scharpe S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy B: Higher alpha-1 antitrypsin, haptoglobin, seruloplasmin and lower retinal binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 1992, 24:183-192.
• [17]Maes M, Scharpe S, Meltzer HY, Cosyns P: Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol Psychiatry 1993, 34:690-701.
• [18]Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P: Relationships between interleukin-6 activity, acute phase proteins and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993, 49:11-27.
• [19]Maes M, Delanghe J, Scharpe S, Meltzer HY, Cosyns P, Suy E, Bosmans E: Haptoglobin phenotypes and gene frequencies in unipolar major depression. Am J Psychiatry 1994, 151:112-116.
• [20]Maes M, Delanghe J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S: Aute phase proteins in schizophrenia, mania and major depression modulation by psychotropic drugs. Psychiatry Res 1997, 66:1-11.
• [21]Song C, Dinan T, Leonard BE: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 1994, 30:283-288.
• [22]Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW: Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013, 18(6):692-699.
• [23]Maes M, Bosmans E, Suy E, Minner B, Raus J: Immune cell parameters in severely depressed patients: negative findings. J Affect Disord 1989, 17:121-128.
• [24]Maes M, Meltzer HY, Stevens W, Calabrese J, Cosyns P: Natural killer cell activity in major depression: relation to circulating natural killer cells. Cellular indices of the immune response, and depressive phenomenology. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:717-730.
• [25]Maes M, Meltzer HY, Scharpe S, Cooreman W, Uyttenbroeck W, Suy E, Vandervorst C, Calabrese J, Raus J, Cosyns P: Psychomotor retardation, anorexia, weight loss, sleep disturbances and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res 1993, 47:229-241.
• [26]Mc Adams C, Leonard BE: Neutrophil and monocyte phagocytosis in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17:971-984.
• [27]Seidel A, Arolt V, Hunstiger M, Rink L, Bechnisch A, Kirchner H: Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 1996, 94(3):198-204.
• [28]Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, Kirchner H: Inflammatory markers in major depression and melancholia. J Affect Disord 2001, 63:93-102.
• [29]Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS: Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause. The Harvard Study of Mood and Cycles. Arch Gen Psychiatry 2003, 60:29-36.
• [30]Schmidt PJ, Murphy JH, Haq N, Rubinow DR, Danaceau MA: Stressful life events, personal losses and perimenopause related depression. Arch Womens Ment health 2004, 7(1):19-26.
• [31]Freeman EW, Sammel M, Liu L, Gracia CR, Nelson DB, Hollander L: Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004, 61:62-70.
• [32]Freeman EW, Sammel MD, Lin H, Nelson DB: Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006, 63:375-382.
• [33]Freeman EW: Associations of depression with the transition to menopause. Menopause 2010, 17(4):823-827.
• [34]Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999, 100:717-722.
• [35]Dreon DM, Slavin JL, Phinney SD: Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003, 73:1245-1252.
• [36]Jilma B, Dimberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG, Kapiotis S, Wagner OF: Menstrual cycle associated changes in blood levels of interleukin-6, alpha 1 acid glucoprotein and C-reactive protein. J Lab Clin Med 1997, 130:69-75.
• [37]Ozturk O, Eraslan D, Mete HE, Ozsener S: The risk factors and symptomatology of perimenopausal depression. Maturitas 2006, 55(2):180-186.
• [38]Karaoulanis SE, Daponte A, Rizouli KA, Rizoulis AA, Lialios GA, Theodoridou CT, Christakopoulos C, Angelopoulos NV: The role of cytokines and hot flashes in perimenopausal depression. Annal Gen Psychiatry 2012, 11:9. BioMed Central Full Text
• [39]Ushiroyama T, Ikeda A, Ueki M: Elevated plasma interleukin 6 (IL-6) and soluble IL-6 receptor concentrations in menopausal women with and without depression. Int J Gynecol Obstet 2002, 79:51-52.
• [40]Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662.
• [41]Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004, 291:2947-2958.
• [42]Brinton RD: Investigative models for determining hormone therapy-induced outcomes in brain. Evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci 2005, 1052:57-74.
• [43]Chang YC, Tzeng SF, Yu L, Huang AM, Lee HT, Huang CC, Ho CJ: Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiol Dis 2006, 24:101-113.
• [44]Li IH, Huang WS, Shiue CY, Huang YY, Liu RS, Chyueh SC, Hu SH, Liao MH, Shen LH, Liu JC, Ma KH: Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET. Neuroimage 2010, 49:1259-1270.
• [45]Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, Yoon SH, Lee JK: Fluoxetine attenuates kainic acid induced neuronal cell death in the mouse hippocampus. Brain Res 2009, 1281:108-116.
• [46]Chen SJ, Kao CL, Chang YL, Yen CJ, Shui JW, Chien CS, Chen IL, Tsai TH, Ku HH, Chiou SH: Anti depressant administration modulates neural stem cell survival and serotoninergic differentiation through bcl-2. Curr Neurovasc Res 2007, 4:19-29.
• [47]Zhang F, Zhou H, Wilson BL, Shi JS, Hong JS, Gao HM: Fluoxetine protect neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 2012, 18S1:S213-S217.
• [48]Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK: Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009, 87:1037-1045.
• [49]Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, Duman RS: Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci 2002, 22:3673-3682.
• [50]Taler M, Miron O, Gil-Ad I, Weizman A: Neurocognitive and procognitive effects of sertraline: In vitro and in vivo studies. Neurosci Lett 2013, 550:93-97.
• [51]Erdem M, Celic C, Cayci T, Ozderim B, Kurt YG, Akgul EO, Yaman H, Balikci A, Uzun O: Serum haptoglobin levels in patients with melancholic and nonmelancholic major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2011, 35:944-947.
• [52]Banger M: Affective syndromes during perimenopause. Maturitas 2002, 41(S):S13-S18.